DIP
VRTX icon

Davis Investment Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Davis Investment Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.15M Sell
2,307
-9
-0.4% -$3.99K 0.35% 47
2026
Q1 		$1.03M Sell
2,316
-240
-9% -$112K 0.37% 49
2025
Q4 		$1.16M Buy
2,556
+27
+1% +$11.6K 0.4% 46
2025
Q3 		$1.02M Buy
2,529
+1,557
+160% +$651K 0.35% 47
2025
Q2 		$440K Hold
972
– – 0.16% 119
2025
Q1 		$482K Hold
972
– – 0.21% 97
2024
Q4 		$398K Hold
972
– – 0.17% 88
2024
Q3 		$449K Sell
972
-3,940
-80% -$1.89M 0.19% 83
2024
Q2 		$2.4M Buy
4,912
+574
+13% +$249K 0.99% 16
2024
Q1 		$1.72M Buy
4,338
+5
+0.1% +$2.11K 0.75% 22
2023
Q4 		$1.8M Buy
4,333
+97
+2% +$35.8K 0.87% 18
2023
Q3 		$1.5M Buy
4,236
+206
+5% +$72K 0.8% 18
2023
Q2 		$1.46M Hold
4,030
– – 0.7% 25
2023
Q1 		$1.27M Sell
4,030
-200
-5% -$60K 0.67% 25
2022
Q4 		$1.27M Buy
+4,230
New +$1.29M 0.64% 25

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Davis Investment Partners's VRTX Position: Q2 2026 in Review

Davis Investment Partners reduced its Vertex Pharmaceuticals (VRTX) stake by 0.39% in Q2 2026, selling an estimated $3.99K and leaving 2,307 shares worth $1.15M. The position accounts for 0.35% of the portfolio, ranked #47.

Davis Investment Partners first reported a position in VRTX in Q4 2022 and has held it in 15 quarters since. The position peaked at $2.4M in Q2 2024. 1,749 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Davis Investment Partners held 2,307 shares of Vertex Pharmaceuticals worth $1.15M as of Q2 2026.
  • Davis Investment Partners sold 9 Vertex Pharmaceuticals shares in Q2 2026, an estimated $3.99K.
  • Vertex Pharmaceuticals made up 0.35% of Davis Investment Partners's portfolio in Q2 2026, its #47 holding.
  • Davis Investment Partners first reported a position in Vertex Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
  • Davis Investment Partners's Vertex Pharmaceuticals position peaked at $2.4M in Q2 2024.
  • 1,749 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Davis Investment Partners's 13F filing for Q2 2026, filed 7 Aug 2026.